{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:00:59Z","timestamp":1779264059383,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.amjmed.2020.03.056","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T08:50:58Z","timestamp":1589359858000},"page":"1322-1327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-9581","authenticated-orcid":false,"given":"Madeleine","family":"Alder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Bavishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-6188","authenticated-orcid":false,"given":"Katelyn","family":"Zumpf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-892X","authenticated-orcid":false,"given":"Jonna","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amjmed.2020.03.056_bib0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamacardio.2019.0911","article-title":"2018 American Heart Association\/American College of Cardiology\/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention","volume":"4","author":"Grundy","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2020.03.056_bib0002","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.amjmed.2020.03.056_bib0003","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.amjmed.2020.03.056_bib0004","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"x","key":"10.1016\/j.amjmed.2020.03.056_bib0005","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2020.03.056_bib0006","first-page":"40","article-title":"meta: An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"issue":"3","key":"10.1016\/j.amjmed.2020.03.056_bib0007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"11","key":"10.1016\/j.amjmed.2020.03.056_bib0008","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2004.11.001","article-title":"Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial","volume":"26","author":"Ballantyne","year":"2004","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.amjmed.2020.03.056_bib0009","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.056_bib0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-120-7-199404010-00002","article-title":"Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients","volume":"120","author":"Sprecher","year":"1994","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.amjmed.2020.03.056_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.amjmed.2020.03.056_bib0012","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.amjmed.2020.03.056_bib0013","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc11-s237","article-title":"Role of bile acid sequestrants in the treatment of type 2 diabetes","volume":"34","author":"Handelsman","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.amjmed.2020.03.056_bib0014","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","article-title":"Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis","volume":"8","author":"Ross","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.amjmed.2020.03.056_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ecl.2008.11.007","article-title":"Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety","volume":"38","author":"Hou","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.amjmed.2020.03.056_bib0016","first-page":"62","article-title":"Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus","volume":"40","author":"Brunetti","year":"2015","journal-title":"P T"},{"issue":"23","key":"10.1016\/j.amjmed.2020.03.056_bib0017","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1001\/jama.1989.03420230073029","article-title":"Cholesterol-lowering effects of psyllium hydrophilic mucilloid. Adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia","volume":"261","author":"Bell","year":"1989","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjmed.2020.03.056_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4158\/EP.13.1.11","article-title":"Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance","volume":"13","author":"Rivers","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.amjmed.2020.03.056_bib0019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/clc.4960240610","article-title":"Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia","volume":"24","author":"Davidson","year":"2001","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjmed.2020.03.056_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1998.00294.x","article-title":"Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care","volume":"243","author":"Eriksson","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjmed.2020.03.056_bib0021","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jama.1988.03410030075032","article-title":"A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III","volume":"260","year":"1988","journal-title":"Jama"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320303727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320303727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:21:41Z","timestamp":1757582501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934320303727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0002934320303727"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.056","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}